ArticleClinical cancer research : an official journal of the American Association for Cancer Research2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 118 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
118 citing papers in PubMed, 4 syntheses or guidelines pooled it, 177 citations in OpenAlex.
- New emerging treatment options for metastatic melanoma: a systematic review and meta-analysis of skin cancer therapies.Archives of dermatological research · 2024Pooled it
- Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.Frontiers in endocrinology · 2021Pooled it
- Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.Frontiers in medicine · 2020Pooled it
- Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.Melanoma research · 2019Pooled it
- Trial
- Machine learning-based development and validation of a scoring system for progression-free survival in liver cancer.Hepatology international · 2020Trial
- Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma.Clinical and experimental immunology · 2019Trial
- Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.Cancer immunology, immunotherapy : CII · 2017Trial
- Drug Delivery Engineering Strategies Targeting CD4+/CD8+ T Cell Exhaustion to Improve the Tumor Immunosuppressive Microenvironment.International journal of nanomedicine · 2026Review
- Cytotoxic T lymphocytes and their dual role in modulating blood-brain barrier integrity in immune-mediated neurological pathologies.Journal of translational medicine · 2025Review
- GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8British journal of cancer · 2025Article
- Metabolism and Immune Suppressive Response in Liver Cancer.Biomedicines · 2025Review
- A Consolidated Review of Contemporary Targeted and Immunotherapeutic Options for Melanoma.Biomedicines · 2025Review
- Transcriptomic and proteomic characterization of cell and protein biomarkers of checkpoint inhibitor-induced liver injury.Cancer immunology, immunotherapy : CII · 2025Observational
- Review
- T cell dynamics with neoadjuvant immunotherapy in head and neck cancer.Nature reviews. Clinical oncology · 2025Review
- Methodological and conceptual considerations for examining the α-FAtE scoring in unresectable hepatocellular carcinoma.Journal for immunotherapy of cancer · 2025Article
- Transcriptomic signatures in peripheral CD4Frontiers in immunology · 2025Article
- Melanoma's New Frontier: Exploring the Latest Advances in Blood-Based Biomarkers for Melanoma.Cancers · 2024Review
- CD4Trends in cancer · 2024Review
58 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 3 countries.
Funding
Abstract
purposeTo investigate changes of peripheral blood biomarkers and their impact on clinical outcome following treatment with ipilimumab in advanced melanoma patients. EXPERIMENTAL
designChanges in blood counts and the frequency of circulating immune cell populations analyzed by flow cytometry were investigated in 82 patients to compare baseline values with different time-points after starting ipilimumab. Endpoints were overall survival (OS) and best clinical response. Statistical calculations were done by Wilcoxon-matched pairs tests, Fisher exact test, Kaplan-Meier analysis, and Cox regression analysis.
resultsIncreases in absolute lymphocyte counts (ALC) 2 to 8 weeks (P = 0.003) and in percentages of CD4
conclusionsIncreases of ALC observed 2 to 8 weeks after initiation of ipilimumab and delayed increases in CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.